The Application of a Synthetic Biodegradable Temporizing Matrix in Extensive Burn Injury: A Unicenter Experience of 175 Cases.

Objectives: Addressing extensive and deep burn wounds poses considerable challenges for both patients and surgeons. The NovoSorb® Biodegradable Temporizing Matrix (BTM) emerged as a novel dermal substitute and has been subjected to evaluation in large burn wound cases, with a specific focus on identifying risk factors associated with suboptimal take rates. Methods: All patients with burn wounds greater than 10% body surface that underwent BTM treatment between March 2020 and November 2023 were eligible for inclusion. Univariate analyses and linear regression models were employed to discern risk factors and predictors influencing the take rates of both the BTM and split-thickness skin grafts (STSGs). Results: A total of 175 patients (mean age 56.2 ± 19.8 years, 70.3% male) were evaluated. The mean take rates of the BTM and STSGs were 82.0 ± 24.7% and 87.3 ± 19.0%, respectively. There were significant negative correlations between BTM take and the number of surgeries before BTM application (r = -0.19, p = 0.01), %TBSA and STSG take (r = -0.36, p = <0.001) and significant positive correlations between BTM and STSG take (r = 0.41, p ≤ 0.001) in addition to NPWT and STSG take (r = 0.21, p = 0.01). Multivariate regression analyses showed that a larger number of surgeries prior to BTM application (OR -3.41, 95% CI -6.82, -0.03, p = 0.04) was associated with poorer BTM take. Allograft treatment before BTM application (OR -14.7, 95% CI -23.0, -6.43,p = 0.01) and failed treatment with STSG before BTM application (OR -20.8, 95% CI -36.3, -5.23, p ≤ 0.01) were associated with poorer STSG take, whereas higher BTM take rates were associated with overall higher STSG take (OR -0.15, 95% 0.05, 0.26, p = 0.01). The Meek technique was used in 24 patients and showed similar take rates (BTM: 76.3 ± 28.0%, p = 0.22; STSG: 80.7 ± 21.1, p = 0.07). Conclusions: This study summarizes our findings on the application of a BTM in the context of large burn wounds. The results demonstrate that successful treatment can be achieved even in patients with extensive burns, resulting in satisfying take rates for both the BTM and STSG. The data underscore the importance of promptly applying a BTM to debrided wounds and indicate good results when using Meek.

NovoSorb® Biodegradable Temporising Matrix (BTM): What we learned from the first 300 consecutive cases.

INTRODUCTION: Extensive full-thickness soft-tissue defects remain a challenge in reconstructive surgery. NovoSorb® Biodegradable Temporising Matrix (BTM) represents a novel dermal substitute and was evaluated in wounds deriving from different aetiologies and to highlight risk factors for poor take rates. METHODS: All patients treated with BTM at our department between March 2020 and October 2022 were included. Differences in univariate and linear regression models identified predictors and risk factors for take rates of BTM and split-thickness skin grafts (STSG). RESULTS: Three hundred patients (mean age 54.2 ± 20.1 years, 66.3% male, 59.7% burns, 19.7% trauma and 20.6% others) were evaluated. Mean take rates of BTM and STSG after BTM delamination were 82.7 ± 25.2% and 86.0 ± 22.6%, respectively. Multiple regression analyses showed that higher body mass index (BMI, OR 0.43, 95% CI 0.86, -0.01, p = 0.44), prior allograft transplantation (OR 15.12, 95% CI 26.98, -3.31, p = 0.041), longer trauma-to-BTM-application intervals (OR 0.01, 95% CI 0.001, -0.001, p = 0.038), positive wound swabs before BTM (OR 7.15, 95% CI 13.50, -0.80, p = 0.028) and peripheral artery disease (OR 10.80, 95% CI 18.63, -2.96, p = 0.007) were associated with poorer BTM take. Higher BMI (OR 0.40, 95% CI 0.76, -0.08, p = 0.026), increasing BTM graft surface areas (OR 0.58, 95% CI -1.00, -0.17, p = 0.005), prior allograft (OR 12.20, 95% CI -21.99, -2.41, p = 0.015) or autograft transplantations (OR 22.42, 95% CI 38.69, -6.14, p = 0.001), tumour as the aetiology of the wound (OR 37.42, 95% CI 57.41, -17.83, p = 0.001), diabetes (OR 6.64, 95% CI 12.80, -0.48, p = 0.035) and impaired kidney function (OR 5.90, 95% CI 10.94, -0.86, p = 0.021) were associated with poorer STSG take after delamination of BTM, whereas higher BTM take rates were associated with better STSG take (OR 0.40, 95% CI 0.31,0.50, p < 0.001). CONCLUSION: Extensive complex wounds of different aetiologies unsuitable for immediate STSG can be successfully reconstructed by means of two-staged BTM application and subsequent skin grafting. Importantly, presence of wound contamination or infection and prior allograft coverage appear to jeopardise good BTM and STSG take.

AORTIC SMOOTH MUSCLE CELLS PRODUCED ELASTIC FIBERS IN THREE-DIMENSIONAL CULTURE / 解剖学报

Objective To Study if aortic smooth muscle cells(ASMC) can produce elastic fibers in three-dimensional culture imitating the dermis substitute. Methods Primary culture of ASMCs were obtained by explanting of thoracic aortae from one-week old SD rats. ?-actin immunocytochemistry was used to approve the smooth muscle cells. After subculture, ASMCs were mixed with gels composed of collagen, chitin and glucosaminoglycans, then, three-dimensional culture was carried out. After 1 week and 2 weeks, Gomori aldehyde fuchsin staining and elastin immunocytochemistry were applied to detect the elastic fibers in the ASMC-collagen gels. Results More than 98% of the cultured cells were approved as smooth muscle cells by ?-actin immunocytochemistry. After both 1 and 2 weeks of three-dimentional culture, elastic fibers were detected in the ASMC-collagen gels by both stainings.Conclusion ASMCs can synthesize elastin and produce elastic fiber in three-dimentional culture imitating the dermis substitute.

THE STUDY ON TRANSPLANTATION OF THREE-DIMENTIONAL CULTURED ASMC-COLLAGEN GEL TO SUBCUTANEOUS / 解剖学报

Objective To investigate if aortic smooth muscle cells (ASMCs) cultured three-dimentionally with collagen gel can still produce elastic fibers and the acceptance of hosts after transplantated in subcutaneous of rats. Methods AMSC-collagen gels that had been cultured for 2 weeks by three-dimentionally imitating the dermis substitute were transplanted to rats subscutaneous. After 4,7,10,14 and 28 days, the transplantations were examined via HE staining, Gomori aldehyde fuchsin staining, ?-actin immunohistochemistry and elastin immunohistochemistry. Results The amount of elastic fibers increased significantly in the week, whereas on the 28th day, no elastic fibers were detected.There was no remarkable leucocyte infiltration around the ASMC-collagen gel during 28 days.Conclusion Further studies are needed to explore the ASMC-collagen gels as a kind of elastic dermis substitute.